title: Effects of growth factors and receptor blockade on gastrointestinal cancer.
abstract: The advent of recombinant peptide technology offers the potential to use one or several peptides to treat a variety of gastrointestinal conditions. However, although cell culture and animal models have shown proof of concept, we are still at a relatively early stage in translating their use to standard clinical practice. Similarly, peptide and non-peptide antagonists of growth factor receptors show great potential as novel antichemotherapy agents. However, their actual place in clinical practice has yet to be established.
authors.affiliation: Gastroenterology Section, Division of Medicine, Imperial College London, Hammersmith Hospital, London, UK. r.playford@imperial.ac.uk
authors.forename: R J
authors.initials: RJ
authors.lastname: Playford
authors.forename: H
authors.initials: H
authors.lastname: Wassan
authors.forename: S
authors.initials: S
authors.lastname: Ghosh
mesh_terms: D066246:ErbB Receptors / Q000378:metabolism; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006131:Growth Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006133:Growth Substances / Q000009:adverse effects / Q000819:agonists*; D006801:Humans; D010455:Peptides / Q000378:metabolism / Q000627:therapeutic use; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors*; D011995:Recombination, Genetic; D012307:Risk Factors; D015398:Signal Transduction / Q000502:physiology
chemical_list: D006131:Growth Inhibitors; D006133:Growth Substances; D010455:Peptides; D017978:Receptors, Growth Factor; D066246:ErbB Receptors